UY27068A1 - Composiciones farmacéuticas de un agonista del receptor de nmda - Google Patents
Composiciones farmacéuticas de un agonista del receptor de nmdaInfo
- Publication number
- UY27068A1 UY27068A1 UY27068A UY27068A UY27068A1 UY 27068 A1 UY27068 A1 UY 27068A1 UY 27068 A UY27068 A UY 27068A UY 27068 A UY27068 A UY 27068A UY 27068 A1 UY27068 A1 UY 27068A1
- Authority
- UY
- Uruguay
- Prior art keywords
- disease
- dementia
- pharmaceutical compositions
- alzheimer
- surgery
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N 1-propanol Substances CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 abstract 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 238000007675 cardiac surgery Methods 0.000 abstract 1
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 230000001010 compromised effect Effects 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25537200P | 2000-12-13 | 2000-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY27068A1 true UY27068A1 (es) | 2002-07-31 |
Family
ID=22968017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY27068A UY27068A1 (es) | 2000-12-13 | 2001-12-12 | Composiciones farmacéuticas de un agonista del receptor de nmda |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US6635270B2 (et) |
| EP (1) | EP1347760B1 (et) |
| JP (1) | JP2004515529A (et) |
| KR (1) | KR100533407B1 (et) |
| CN (1) | CN1273135C (et) |
| AP (1) | AP1235A (et) |
| AR (1) | AR035607A1 (et) |
| AT (1) | ATE296629T1 (et) |
| AU (2) | AU1845402A (et) |
| BG (1) | BG107788A (et) |
| BR (1) | BR0116085A (et) |
| CA (1) | CA2431172A1 (et) |
| CZ (1) | CZ20031543A3 (et) |
| DE (1) | DE60111265T2 (et) |
| DO (1) | DOP2001000300A (et) |
| DZ (1) | DZ3484A1 (et) |
| EA (1) | EA006489B1 (et) |
| EC (1) | ECSP034655A (et) |
| EE (1) | EE200300284A (et) |
| ES (1) | ES2239648T3 (et) |
| GE (1) | GEP20053568B (et) |
| HR (1) | HRP20030473A2 (et) |
| HU (1) | HUP0400645A2 (et) |
| IL (1) | IL155810A0 (et) |
| IS (1) | IS6811A (et) |
| MA (1) | MA26970A1 (et) |
| MX (1) | MXPA03005257A (et) |
| NO (1) | NO20032678L (et) |
| NZ (1) | NZ525742A (et) |
| OA (1) | OA12414A (et) |
| PA (1) | PA8534901A1 (et) |
| PE (1) | PE20020710A1 (et) |
| PL (1) | PL362080A1 (et) |
| PT (1) | PT1347760E (et) |
| SK (1) | SK6982003A3 (et) |
| TN (1) | TNSN01173A1 (et) |
| UA (1) | UA73619C2 (et) |
| UY (1) | UY27068A1 (et) |
| WO (1) | WO2002047685A2 (et) |
| YU (1) | YU41103A (et) |
| ZA (1) | ZA200303892B (et) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20150037T4 (hr) | 2003-04-08 | 2022-09-02 | Progenics Pharmaceuticals, Inc. | Farmaceutske formulacije koje sadrže metilnaltrekson |
| TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
| TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
| TW200811144A (en) * | 2006-06-09 | 2008-03-01 | Wyeth Corp | Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
| TW200808741A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| US20080262228A1 (en) * | 2006-11-28 | 2008-10-23 | Wyeth | Metabolites of 5-fluoro-8- quinoline and methods of preparation and uses thereof |
| TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
| CN101317844B (zh) * | 2007-06-08 | 2010-11-17 | 章劲夫 | 化合物(+)-5-甲基-10，11-二氢-5H-二苯并〔a，d〕环庚烯-5，10-亚胺在制备避孕药物中的应用 |
| BRPI0918868B8 (pt) | 2008-09-18 | 2021-05-25 | Naurex Inc | compostos moduladores do receptor de nmda e composições compreendendo os mesmos |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| EP2542254B1 (en) | 2010-02-11 | 2018-09-26 | Northwestern University | Nmda receptor agonists and uses thereof |
| CN102586243A (zh) * | 2012-03-08 | 2012-07-18 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种预防电磁辐射致脑损伤的标志物 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| WO2014120789A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| SG11201505862TA (en) | 2013-01-29 | 2015-08-28 | Naurex Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| LT3514158T (lt) | 2013-01-29 | 2023-02-10 | Aptinyx Inc. | Spirolaktaminiai nmda receptoriaus moduliatoriai ir jų panaudojimas |
| PE20151427A1 (es) | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
| MX2015009773A (es) | 2013-01-29 | 2016-08-05 | Aptinyx Inc | Moduladores de receptores nmda de espiro-lactama y sus usos. |
| WO2015099381A1 (ko) | 2013-12-23 | 2015-07-02 | 주식회사 삼양바이오팜 | 팔로노세트론을 함유하는 약학 조성물 |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| KR102128675B1 (ko) | 2016-05-19 | 2020-06-30 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| WO2018026792A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |
| AU2017306164B2 (en) | 2016-08-01 | 2021-10-21 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam NMDA modulators and methods of using same |
| EP3490974B1 (en) | 2016-08-01 | 2023-12-06 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda receptor modulators and uses thereof |
| SG10202101055VA (en) | 2016-08-01 | 2021-03-30 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| IL286107B2 (en) | 2016-08-01 | 2024-09-01 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and usesthereof |
| JP7210599B2 (ja) | 2018-01-31 | 2023-01-23 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用 |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5272160A (en) * | 1989-05-17 | 1993-12-21 | Pfizer Inc | 2-piperidino-1-alkanol derivatives as antiischemic agents |
| US5710168A (en) * | 1991-10-23 | 1998-01-20 | Pfizer Inc. | 2-piperidino-1-alkanol derivatives as neuroprotective agents |
| HUP9802862A3 (en) * | 1995-08-11 | 1999-05-28 | Pfizer | (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate and pharmaceutical compositions containing it for treating cns disorders |
| TW450807B (en) * | 1995-09-15 | 2001-08-21 | Pfizer | Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents |
-
2001
- 2001-05-12 UA UA2003065485A patent/UA73619C2/uk unknown
- 2001-12-05 HU HU0400645A patent/HUP0400645A2/hu unknown
- 2001-12-05 PL PL01362080A patent/PL362080A1/xx not_active Application Discontinuation
- 2001-12-05 US US10/010,827 patent/US6635270B2/en not_active Expired - Fee Related
- 2001-12-05 HR HR20030473A patent/HRP20030473A2/hr not_active Application Discontinuation
- 2001-12-05 CZ CZ20031543A patent/CZ20031543A3/cs unknown
- 2001-12-05 EA EA200300514A patent/EA006489B1/ru not_active IP Right Cessation
- 2001-12-05 MX MXPA03005257A patent/MXPA03005257A/es active IP Right Grant
- 2001-12-05 OA OA1200300145A patent/OA12414A/en unknown
- 2001-12-05 IL IL15581001A patent/IL155810A0/xx unknown
- 2001-12-05 DE DE60111265T patent/DE60111265T2/de not_active Expired - Fee Related
- 2001-12-05 EP EP01270205A patent/EP1347760B1/en not_active Expired - Lifetime
- 2001-12-05 AU AU1845402A patent/AU1845402A/xx active Pending
- 2001-12-05 NZ NZ525742A patent/NZ525742A/en unknown
- 2001-12-05 KR KR10-2003-7007874A patent/KR100533407B1/ko not_active Expired - Fee Related
- 2001-12-05 GE GE5171A patent/GEP20053568B/en unknown
- 2001-12-05 CA CA002431172A patent/CA2431172A1/en not_active Abandoned
- 2001-12-05 AT AT01270205T patent/ATE296629T1/de not_active IP Right Cessation
- 2001-12-05 EE EEP200300284A patent/EE200300284A/et unknown
- 2001-12-05 JP JP2002549256A patent/JP2004515529A/ja active Pending
- 2001-12-05 YU YU41103A patent/YU41103A/sh unknown
- 2001-12-05 PT PT01270205T patent/PT1347760E/pt unknown
- 2001-12-05 WO PCT/IB2001/002359 patent/WO2002047685A2/en not_active Ceased
- 2001-12-05 DZ DZ013484A patent/DZ3484A1/fr active
- 2001-12-05 SK SK698-2003A patent/SK6982003A3/sk unknown
- 2001-12-05 CN CNB018203922A patent/CN1273135C/zh not_active Expired - Fee Related
- 2001-12-05 BR BR0116085-0A patent/BR0116085A/pt not_active IP Right Cessation
- 2001-12-05 AU AU2002218454A patent/AU2002218454B2/en not_active Ceased
- 2001-12-05 ES ES01270205T patent/ES2239648T3/es not_active Expired - Lifetime
- 2001-12-10 DO DO2001000300A patent/DOP2001000300A/es unknown
- 2001-12-11 PE PE2001001235A patent/PE20020710A1/es not_active Application Discontinuation
- 2001-12-11 AR ARP010105748A patent/AR035607A1/es unknown
- 2001-12-12 UY UY27068A patent/UY27068A1/es not_active Application Discontinuation
- 2001-12-12 TN TNTNSN01173A patent/TNSN01173A1/fr unknown
- 2001-12-13 AP APAP/P/2001/002376A patent/AP1235A/en active
- 2001-12-13 PA PA20018534901A patent/PA8534901A1/es unknown
-
2003
- 2003-05-08 IS IS6811A patent/IS6811A/is unknown
- 2003-05-09 BG BG107788A patent/BG107788A/bg unknown
- 2003-05-20 ZA ZA200303892A patent/ZA200303892B/en unknown
- 2003-06-03 MA MA27191A patent/MA26970A1/fr unknown
- 2003-06-12 NO NO20032678A patent/NO20032678L/no not_active Application Discontinuation
- 2003-06-13 EC EC2003004655A patent/ECSP034655A/es unknown
- 2003-08-19 US US10/643,441 patent/US20040039022A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27068A1 (es) | Composiciones farmacéuticas de un agonista del receptor de nmda | |
| WO2002051439A3 (en) | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor | |
| ES2156162T3 (es) | Compuestos activos en un nuevo sitio sobre canales del calcio accionados por un receptor, utiles para el tratamiento de trastornos y enfermedades neurologicas. | |
| SI1326613T2 (sl) | Uporaba substituiranih imidazo/1,2-a/piridin-, -pirimidin - in -pirazin-3-il-aminskih derivatov za pripravo zdravil za inhibiranje NOS | |
| WO2007064453A3 (en) | Methods and systems for ultrasound delivery through a cranial aperture | |
| WO2009067323A8 (en) | Systems, methods and devices for a skull/brain interface | |
| TW201006431A (en) | Flexible stabilization device including a rod and tool for manufacturing the rod | |
| WO2006113471A3 (en) | N-alkyl-azacycloalkyl nmda/nr2b antagonists | |
| BR0116311A (pt) | Derivados de piperidina como subtipo de antagonistas de n-metil-d-aspartato selectivos | |
| WO2006100677A3 (en) | Device and method for pupil size modulation | |
| DE102006026288A1 (de) | Knochenleitungshörgrät | |
| CA2527093A1 (en) | 3-fluoro-piperidines as nmda/nr2b antagonists | |
| MXPA03000439A (es) | Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida. | |
| JP2004524357A5 (et) | ||
| EP1201240A3 (en) | Heterocyclic derivatives useful as pharmaceutical agents | |
| WO2008125902A3 (en) | Peripheral and neural inflammatory crosstalk | |
| AU2003273310A1 (en) | Substituted aminoethers for the treatment of alzheimer's disease | |
| WO2007106862A3 (en) | The use of statins to stimulate neurogenesis | |
| JO2260B1 (en) | Piperidine ethanesulfonyl derivatives | |
| CR6982A (es) | Composiciones farmaceuticas de un agonista del receptor de nmda. | |
| CN219109889U (zh) | 一种腿部牵引架 | |
| CN215079548U (zh) | 骨科临床用手术镊 | |
| CN210044378U (zh) | 一种可调长短的骨科大夫用腿部观察架 | |
| CN223529609U (zh) | 一种骨科外固定成型夹板结构 | |
| CN117357231B (zh) | 一种具有缓冲效果的骨科金属内植入物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20141106 |